Osmotic release oral system-methylphenidate improves neural activity during low reward processing in children and adolescents with attention-deficit/hyperactivity disorder.
Osmotic release oral system-methylphenidate improves neural activity during low reward processing in children and adolescents with attention-deficit/hyperactivity disorder.
复制标题
DOI：
10.1016/j.nicl.2013.03.004
复制
发表时间：
2013
影响因子：
4.2
通讯作者：
Tomoda, Akemi
中科院分区：
文献类型：
--
作者：
Mizuno, Kei;Yoneda, Tetsuya;Komi, Masanori;Hirai, Toshinori;Watanabe, Yasuyoshi;Tomoda, Akemi
关键词：
注意力缺陷多动障碍（attention deficit/hyperactivity disorder，ADHD）是一种以注意力不集中、多动/冲动和奖赏系统功能受损为特征的神经行为障碍，表现为延迟厌恶和低奖赏敏感性。ADHD的药物治疗包括哌醋甲酯（MPH）或渗透释放口服系统-MPH（OROS-MPH），其通过阻断突触外多巴胺和去甲肾上腺素的再摄取来增加它们的水平。虽然先前的功能性磁共振成像（fMRI）研究表明，急性治疗MPH改变了ADHD儿童和青少年延迟厌恶过程中丘脑核的激活，但相对较长时间的OROS-MPH治疗对延迟厌恶和奖励敏感性的影响仍不清楚。因此，我们在奖励敏感性范例中用fMRI评估了17名ADHD儿童和青少年（平均年龄，13.3 ± 2.2岁）和17名年龄和性别匹配的健康对照（平均年龄，13.0 ± 1.9岁）在OROS-MPH治疗3个月前后的大脑激活，该范例包括高金钱奖励和低金钱奖励条件。结果发现，ADHD患者治疗前在低金钱奖励条件下丘脑和丘脑的激活减弱，治疗后恢复到正常对照组水平。观察到的大脑活动变化与ADHD症状评分的改善有关，这些评分来自日本版本的ADHD评定量表-IV。这些结果表明，OROS-MPH治疗相对较长的时间是有效的控制奖励敏感性的儿童和青少年多动症。注意力缺陷多动障碍（ADHD）具有低奖励敏感性。在低金钱奖励时，丘脑和丘脑核的活动减少。哌醋甲酯口服渗透释放系统（OROS-MPH）是一种治疗ADHD的药物。OROS-MPH治疗3个月后，大脑活动和ADHD症状得到改善。长期OROS-MPH治疗可能会改变儿童ADHD的大脑活动。
Attention-deficit/hyperactivity disorder (ADHD) is neurobehavioral disorder characterized by inattention, hyperactivity/impulsivity and impaired reward system function, such as delay aversion and low reward sensitivity. The pharmacological treatment for ADHD includes methylphenidate (MPH), or osmotic release oral system-MPH (OROS-MPH), which increases extrasynaptic dopamine and noradrenaline levels by blocking their reuptake. Although previous functional magnetic resonance imaging (fMRI) studies revealed that acute treatment with MPH alters activation of the nucleus accumbens during delay aversion in children and adolescents with ADHD, the effects a relatively long period of OROS-MPH treatment on delay aversion as well as reward sensitivity remain unclear. Thus, we evaluated brain activation with fMRI during a reward sensitivity paradigm that consists of high monetary reward and low monetary reward conditions before and after a 3-month treatment with OROS-MPH in 17 children and adolescents with ADHD (mean age, 13.3 ± 2.2) and 17 age- and sex-matched healthy controls (mean age, 13.0 ± 1.9). We found that before treatment there was decreased activation of the nucleus accumbens and thalamus in patients with ADHD during only the low monetary reward condition, which was improved to same level as those of the healthy controls after the treatment. The observed change in brain activity was associated with improved ADHD symptom scores, which were derived from Japanese versions of the ADHD rating scale-IV. These results suggest that treatment with OROS-MPH for a relatively long period is effective in controlling reward sensitivity in children and adolescents with ADHD. Attention deficit/hyperactivity disorder (ADHD) has low reward sensitivity. Activity in thalamus and nucleus accumbens was decreased in low monetary reward. Osmotic release oral system-methylphenidate (OROS-MPH) is a medication for ADHD. Brain activity and ADHD symptoms were improved by 3-month treatment with OROS-MPH. OROS-MPH treatment for long periods may change brain activity of pediatric ADHD.
登录
查看更多内容
影响因子：
25
作者：
Buckholtz, Joshua W.;Treadway, Michael T.;Cowan, Ronald L.;Woodward, Neil D.;Benning, Stephen D.;Li, Rui;Ansari, M. Sib;Baldwin, Ronald M.;Schwartzman, Ashley N.;Shelby, Evan S.;Smith, Clarence E.;Cole, David;Kessler, Robert M.;Zald, David H.
通讯作者：
Zald, David H.
影响因子：
4.8
作者：
Cubillo, Ana;Halari, Rozmin;Rubia, Katya
通讯作者：
Rubia, Katya
影响因子：
5.3
作者：
Bjork, JM;Knutson, B;Hommer, DW
通讯作者：
Hommer, DW
影响因子：
6.9
作者：
Biederman, J;Monuteaux, MC;Faraone, SV
通讯作者：
Faraone, SV
影响因子：
16.2
作者：
Breiter, HC;Aharon, I;Shizgal, P
通讯作者：
Shizgal, P